1. Andersohn F, Konzen C, Garbe E (2007) Systematic review: Agranulocytosis induced by nonchemotherapy drugs. Vol. 146, Annals of Internal Medicine. American College of Physicians: 657–65.
2. Nooijen PMM, Carvalho F, Flanagan RJ (2011) Haematological toxicity of clozapine and some other drugs used in psychiatry. Hum Psychopharmacol 26: 112–9.
3. Mazaira S (2008) Haematological adverse effects caused by psychiatric drugs. Vertex (Buenos Aires, Argentina). 19: 378–86.
4. Vargas A, Ebner M, Gaete T (2017) Agranulocytosis secondary to clozapine: a descriptive study in Chilean patients Agranulocytosis secondary to clozapine: a descriptive study in Chilean patients. Rev Chil Neuro-Psychiat 55: 77–84.
5. Second-generation antipsychotic medications: Pharmacology, administration, and side effects.
6. Myles N, Myles H, Xia S, Large M, Kisely S, Galletly C, et al. (2018) Meta-analysis examining the epidemiology of clozapine-associated neutropenia. Acta Psychiatr Scand 138: 101–9.
7. Pons A, Undurraga J, Batalla A, Bernardo M (2012) Clozapine and agranulocytosis in Spain: do we have a safer population? 5-year hematological follow-up of a cohort of patients treated with clozapine.Rev Psiquiatr Salud Ment 5: 37–42.
8. Munro J, O’Sullivan D, Andrews C, Arana A, Mortimer A, et al. (1999) Active monitoring of 12760 clozapine recipients in the UK and Ireland: Beyond pharmacovigilance. Br J Psychiatry.
9. Coates TD (2018) Drug-induced neutropenia and agranulocytosis - UpToDate 2018: 1–28.
10. Mena CI, Nachar RA, Crossley NA, González-Valderrama AA (2020) Clozapine-associated neutropenia in Latin America: Incidence report of 5380 Chilean users. Int Clin Psychopharmacol 34: 257–63.
11. Alba P (2017) Treatment-resistant schizophrenia: Neutropenia with olanzapine and clozapine, and stabilization with two depot antipsychotics. 28: 141–4.
12. Freudenreich O, McEvoy J (2020) Guidelines for prescribing clozapine in schizophrenia 2020: 1–11.
13. Sultan RS, Olfson M, Correll CU, Duncan EJ (2017) Evaluating the effect of the changes in FDA guidelines for clozapine monitoring. J Clin Psychiatry 78: e933–9.
14. AEMPS (2020) Technical Sheet 1. Name of the Drug 2018.
15. Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J (1998) Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 59: 3–7.
16. Mena CI, Nachar RA, Crossley NA, González-Valderrama AA (2019) Clozapine-associated neutropenia in Latin America: Incidence report of 5380 Chilean users. Int Clin Psychopharmacol 34: 257–63.
17. Barnes TRE, Drake R, Paton C, Cooper SJ, Deakin B, et al. (2020) Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol 34: 3–78.
18. Sultan RS, Olfson M, Correll CU, Duncan EJ (2017) Evaluating the effect of the changes in FDA guidelines for clozapine monitoring. J Clin Psychiatry 78: e933–9.
19. Gibson C, Berliner N (2014) How we evaluate and treat neutropenia in adults. Blood 124: 1251–8.
20. Recommendations (2014) Psychosis and schizophrenia in adults: prevention and management | Guidance. NICE National Institute for Health and Care Excellence NICE.
21. Remington G, Addington D, Honer W, Ismail Z, Raedler T, et al. (2017) Guidelines for the Pharmacotherapy of Schizophrenia in Adults. Can J Psychiatry 62: 604–16.
22. Howes OD, McCutcheon R, Agid O, De Bartolomeis A, Van Beveren NJM, et al. (2017) Treatment-ResistantSchizophrenia: TreatmentResponse and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. Am J Psychiatry 174: 216–29.
23. Galletly C, Castle D, Dark F, Humberstone V, Jablensky A (2016) Killackey E, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Vol. 50, Australian and New Zealand Journal of Psychiatry: 410-72.
24. Ng W, Kennar R, Uetrecht J (2014) Effect of clozapine and olanzapine on neutrophil kinetics: Implications for drug-induced agranulocytosis. Chem Res Toxicol 27: 1104–8.
25. Malhotra K, Vu P, Wang DH, Lai H, Faziola LR (2015) Olanzapine-induced neutropenia. Ment Illn 7: 18–20.